Literature DB >> 8983935

Pharmacokinetics of tolfenamic acid in pediatric patients after single oral dose.

I Niopas1, M Georgarakis, V Sidi-Frangandrea, C Chrisanthopoulos, E Liara.   

Abstract

The pharmacokinetics of tolfenamic acid, a non-steroidal anti-inflammatory drug, were determined following administration of a 1 mg/kg single oral dose of tolfenamic acid suspension to 6 feverish children. Their ages were from 2-14 years (mean 7.5 years) and their weights were from 12-50 kg (mean 29.2 kg). Tolfenamic acid produced a significant fall in temperature (about 2 degrees C) compared to the initial value before oral intake of the drug and was well tolerated without adverse effects. Blood samples for determination of tolfenamic acid concentrations in plasma were obtained at timed intervals for up to 8 h post-dose. Plasma concentrations of tolfenamic acid were determined using a reversed phase HPLC method and pertinent pharmacokinetic parameters were estimated by model-independent standard methods and were the following: the mean peak plasma concentration (Cmax +/- SEM) was 1.09 +/- 0.44 micrograms/ml (range, 0.65-1.63 micrograms/ml) and the mean time (tmax +/- SEM) to reach peak plasma concentration was 1.4 +/- 0.4 h (range, 0.5-3.0 h). The mean area under the plasma concentration-time curve (AUC0-->infinity +/- SEM) was 4.61 +/- 0.40 micrograms.h/ml (range, 2.74-5.98 micrograms.h/ml), the mean elimination half-life (t1/2 +/- SEM) was 2.82 +/- 0.21 h (range, 2.19-3.40 h) and the mean apparent total clearance (CL/F +/- SEM) was 3.83 +/- 0.41 ml/min/kg (range, 2.79-6.08 ml/min/kg).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8983935     DOI: 10.1007/BF03190247

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  Assay of tolfenamic acid and its metabolites by liquid chromatography on dynamically modified silica: application in pharmacokinetics.

Authors:  S H Hansen; S B Pedersen
Journal:  J Pharm Biomed Anal       Date:  1986       Impact factor: 3.935

2.  Pharmacology of tolfenamic acid.

Authors:  T Corell
Journal:  Pharmacol Toxicol       Date:  1994

Review 3.  Tolfenamic acid and leukotriene synthesis inhibition.

Authors:  E Moilanen; H Kankaanranta
Journal:  Pharmacol Toxicol       Date:  1994

4.  Prolonged treatment with tolfenamic acid in inflammatory rheumatic diseases.

Authors:  A Kajander; J Martio; O Mutru; G Gothoni
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

5.  Inhibition of prostaglandin biosynthesis by tolfenamic acid in vitro.

Authors:  I B Lindén; J Parantainen; H Vapaatalo
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

6.  A comparative, double-blind study on tolfenamic acid in the treatment of rheumatoid arthritis.

Authors:  V Rejholec; H Vapaatalo; O Tokola; G Gothoni
Journal:  Scand J Rheumatol Suppl       Date:  1979

7.  Tolfenamic acid. Detection and structure of urinary metabolites.

Authors:  S B Pedersen; B Alhede; O Buchardt; J Møller; K Bock
Journal:  Arzneimittelforschung       Date:  1981

8.  Oral antipyretic therapy: evaluation of the N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and flufenamic acid.

Authors:  S Keinänen; S Similä; K Kouvalainen
Journal:  Eur J Clin Pharmacol       Date:  1978-07-30       Impact factor: 2.953

Review 9.  Biopharmaceutical aspects of tolfenamic acid.

Authors:  S B Pedersen
Journal:  Pharmacol Toxicol       Date:  1994

10.  Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine.

Authors:  B H Larsen; L V Christiansen; B Andersen; J Olesen
Journal:  Acta Neurol Scand       Date:  1990-05       Impact factor: 3.209

View more
  4 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

Authors:  Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2022-09-02       Impact factor: 3.930

3.  Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.

Authors:  Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2007-07-06       Impact factor: 2.953

4.  The Inclusion of Tolfenamic Acid into Cyclodextrins Stimulated by Microenvironmental pH Modification as a Way to Increase the Anti-Migraine Effect.

Authors:  Anna Stasiłowicz; Ewa Tykarska; Natalia Rosiak; Kinga Sałat; Anna Furgała-Wojas; Tomasz Plech; Kornelia Lewandowska; Katarzyna Pikosz; Kamil Pawłowicz; Judyta Cielecka-Piontek
Journal:  J Pain Res       Date:  2021-04-14       Impact factor: 3.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.